Treating ocular toxoplasmosis - Current evidence

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 2, 2009, Pages 312-315

  Stanford, M R ^a   Gilbert, R E ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Current evidence; Ocular toxoplasmosis; Treatment

Indexed keywords

EID: 65549096928     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000200027     Document Type: Article

References (33)

1. Acers TE 1964. Toxoplasmic retinochoroiditis: a double blind therapeutic study. Arch Ophthalmol 71: 58-62.
2. Cocherau-Massin I, LeHoang P, Lautier-Frau M, Zerboun E, Zazoun L, Robinet M, Marcel P, Girard B, Katlama L, Leport C 1992. Ocular toxoplasmosis in human immunodeficiency virus infected patients. Am J Ophthalmol 114: 130-135.
3. Dubey JP, Lindsay DS, Speer CA 1998. Structures of Toxoplasma gondii tachyzoites, bradyzoites and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 11: 267-299.
4. Eyles DE, Coleman N 1955. An evaluation of the curative effects of of pyrimethamine and sulfadiazine, alone and in combination, on experimental mouse toxoplasmosis. Antibiot & Chemotherapy 5: 529-539.
5. Freeman K, Tan HK, Prusa A, Petersen E, Buffolano W, Malm G, Cortina-Borja M, Gilbert R 2008. Predictors of retinochoroiditis in children born with congenital toxoplasmosis; European multicentre study on congenital toxoplasmosis. Paediatrics 121: 1215-1222.
6. Gilbert RE, Stanford MR 2000. Is ocular toxoplasmosis due to prenatal or postnatal infection? Br J Ophthalmol 84: 224-226.
7. Gras L, Gilbert RE, Ades AE, Dunn DT 2001. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 30: 1309-1313.
8. Hogan MJ 1958. Ocular toxoplasmosis. XIV Edward Jackson Memorial Lecture. Am J Ophthalmol 46: 467-494.
9. Holland GN 2004. Toxoplasmosis: a global reassessment. Part 2: Disease manifestations and management. Am J Ophthalmol 137: 1-17.
10. Holland GN, Crespi CM, ten Dam-van, Loon N, Charonis AC, Yu F, Bosch-Dreissen LH, Rothova A 2008. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol 145: 1007-1013.
11. Holland GN, Engstrom RE, Glasgow BJ, Berger BB, Daniels SA, Sidikaro Y, Harmon JA, Fischer DH, Boyer DS, Rao NA 1988. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 106: 653-667.
12. Holland GN, Lewis KG 2002. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 134: 102-114.
13. Howe DK, Sibley LD 1995. Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis 172: 1561-1566.
14. Lakhanpal V, Schocker SS, Nirankari VS 1983. Clindamycin in the treatment of ocular toxoplasmic retinochoroiditis. Am J Ophthalmol 95: 605-613.
15. Luder CGK, Giraldo-Velasquez M, Sendtner M, Gross U 1999. Toxoplasma gondii in primary rat CNS cells: differential contribution of neurones, astrocytes and microglial cells for the intracerebral development and stage differentiation. Exp Parasitol 93: 23-32.
16. McMaster PR, Powers KG, Finerty JF, Lunde MN 1973. The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am J Trop Med Hyg 22: 14-17.
17. Meneceur P, Bouldouyre MA, Aubert D, Villena I, Menotti J, Sauvage V, Garin JF, Derouin F 2008. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine and atovaquone. Antimicrob Agents Chemother 52: 1269-1277.
18. O'Connor GR, Frenkel JK 1976. Editorial: Dangers of steroid treatment in ocular toxoplasmosis. Periocular injections and systemic therapy. Arch Ophthalmol 94: 213.
19. Opremcak EM, Scales DK, Sharpe MR 1992. Trimethoprim-sulphamethoxazole therapy for ocular toxoplasmosis. Ophthalmology 99: 920-925.
20. Pearson PA, Piracha AR, Sen HA, Jaffe GJ 1999. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 106: 148-153.
21. Perkins ES, Smith CH, Schofield PB 1956. Treatment of uveitis with pyrimethamine (Daraprim). Br J Ophthalmol 40: 577-586.
22. Rodriguez A 1981. Photocoagulation in toxoplasmic retinochoroiditis. Am J Ophthalmol 91: 417-418.
23. Rothova A, Bosch-Driessen LE, van Loon NH, Treffers WF 1998. Azithromycin for ocular toxoplasmosis. Br J Ophthalmol 82: 1306-1308.
24. Rothova A, Meenken C, Buitenhuis HJ, Brinkman CJ, Linssen A, Alberts C, Luyendik L, Kijlstra A 1993. Therapy for ocular toxoplasmosis. Am J Ophthalmol 115: 517-523.
25. Ryan RW, Hart WM, Culligan JJ, Gunkel RD, Jacobs L, Cook MK 1954. Diagnosis and treatment of toxoplasmic uveitis. Trans Am Acad Ophth 58: 867-884.
26. Scherrer J, Iliev ME, Halberstadt M, Kodjikian L, Garweg JG 2007. Visual function in ocular toxoplasmosis. Br J Ophthalmol 91: 233-236.
27. Silveira C, Belfort R, Muccioli C, Holland GN, Victora CG, Horta BL, Yu F, Nussenblatt RB 2002. The effect of long-term intermittent trimethoprim/sulphamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 134: 41-46.
28. Spalter HF, Campbell CJ, Noyori KS, Rittler MC, Koester CJ 1966. Prophylactic photocoagulation of recurrent toxoplasmic retinochoroiditis: a preliminary report. Arch Ophthalmol 75: 21-31.
29. Stanford MR, See SE, Jones LV, Gilbert RE 2003. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology 110: 926-932.
30. Stanford MR, Tomlin E, Comyn O, Hollands K, Pavesio C 2005. The visual field in toxoplasmic retinochoroiditis. Br J Ophthalmol 89: 812-814.
31. Tabbara KF, O'Connor GR 1975. Ocular tissue absorption of clindamycin phosphate. Arch Ophthalmol 93: 1180-1185.
32. Tabbara KF, O'Connor GR 1980. Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine. Ophthalmology 87: 129-134.
33. Wolf A, Cowen D, Paige BJ 1939. Human toxoplasmosis: occurrence in infants as an encephalomyelitis; verification by transmission to animals. Science 89: 226-227.